Press Releases Filter Filter Results Year 2023 (3) 2022 (23) 2021 (20) 2020 (38) 2019 (37) 2018 (23) 2017 (25) 2016 (20) 2015 (25) 2014 (26) 2013 (31) 2012 (35) May 18, 2023 Analysis Showcases Potential for More Complete Revascularizations with Impella Compared to IABP during HRPCI April 24, 2023 Pivotal Impella ECP Study Expands Enrollment to Three New Jersey Hospitals February 24, 2023 Abiomed at CRT 2023: Benefits of Impella-Supported High Risk PCI and Impella Innovation December 22, 2022 Johnson & Johnson Completes Acquisition of Abiomed December 21, 2022 FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial December 5, 2022 First Patients in the World Treated with Impella RP Flex with SmartAssist November 1, 2022 Johnson & Johnson to Acquire Abiomed November 1, 2022 Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year October 31, 2022 Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure October 26, 2022 Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare October 20, 2022 Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure October 17, 2022 U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath October 13, 2022 Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support September 20, 2022 Multi-Center, Multi-Society Study of Impella®-Supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77% September 19, 2022 Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81% 1 2 3 4 …
